Analyst Consensus ?
ConsensusBuy44 ratings
Bullish3272.7%
Neutral1125.0%
Bearish12.3%
1 unmapped firm rating excluded from the percentages.
Cencora, Inc. · COR · FY2026 Q4 · Calendar Q4 2026
Cencora leans on specialty growth as FY2027 expansion requires investment
Management’s FY2027 outlook and planned investment rest on continued expansion of specialty pharmaceuticals and provider-service platforms. That growth case is supported by demand and platform additions, but acquisition integration, reimbursement changes and elevated capital spending are material execution risks.
Reported Before market openNYSEHealthcare
$64.98B market cap
80quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $4.58
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $87.95B
Revenue surprise
—
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+4.0%
Event window
SPY move
+1.7%
Same window
Abnormal move
+2.3%
Stock minus SPY
Volume
2.4×
Versus trailing sessions
Subsequent drift
0.0%
Up to 20 sessions
CORSPY benchmark
Ask FN2 about COR FY2026 Q4
Transcript, numbers and history already loaded
What drove COR's +4.0% move after FY2026 Q4 earnings?What changed in COR's guidance and outlook in FY2026 Q4?Give me the bull and bear case for COR after FY2026 Q4 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management reported record FY2026 results and introduced a new operating model with two business segments, saying the resegmentation is intended to improve execution, customer focus and shareholder visibility. The call shifted focus to FY2027, with growth expectations and a $1 billion investment program; the prior quarter had raised FY2026 adjusted EPS guidance and highlighted specialty-platform momentum.
Guidance delta
Management’s FY2027 targets are 3–5% revenue growth, 4–6% operating income growth and 8–10% EPS growth. The prior quarter’s raised FY2026 adjusted EPS guidance was $17.75–$17.95; this call’s analysis describes FY2026 adjusted EPS of $17.97. No beat-or-miss conclusion is drawn here.
Key takeaways
- Management identified specialty pharmaceuticals as the primary growth engine and expects the segment to generate $100 billion in FY2027 revenue.
- OneOncology, iSouth Retina and the planned American Oncology Network acquisition expand the management-services platform and clinical-trial capabilities.
- Management outlined $1 billion of investment in supply chain, digital transformation and MSO infrastructure.
- Management announced a 10% quarterly dividend increase and a $1.25 billion share-repurchase program.
Management priorities
- Complete the American Oncology Network acquisition and finalize the iSouth Retina acquisition.
- Invest in supply-chain, digital and MSO infrastructure.
- Improve execution and customer focus through the new operating model and segment structure.
- Advance the specialty platform and clinical-trial logistics capabilities.
Follow COR with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$354Current
$142Low
$285.89Average
$440High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 5, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Morgan Stanley | Overweight | Overweight | Maintain | Oct 30, 2026 |
| Baird | Outperform | Outperform | Maintain | Oct 22, 2026 |
| Argus Research | Buy | Buy | Maintain | Oct 20, 2026 |
| UBS | Buy | Buy | Maintain | Oct 16, 2026 |
| Leerink Partners | Outperform | Outperform | Maintain | Oct 7, 2026 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Sep 8, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Aug 11, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Aug 7, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Aug 6, 2026 |
| B of A Securities | Neutral | Neutral | Maintain | Jun 24, 2026 |
| Barclays | Overweight | Overweight | Maintain | Jun 10, 2026 |
| Citigroup | Buy | Buy | Maintain | May 7, 2026 |
| Jefferies | Buy | Hold | Upgrade | Jan 22, 2026 |
| TD Cowen | Buy | Buy | Maintain | Nov 10, 2025 |
| Mizuho | Outperform | Outperform | Maintain | Nov 6, 2025 |
| Deutsche Bank | Buy | Buy | Maintain | May 26, 2023 |
| Credit Suisse | Outperform | Outperform | Maintain | May 2, 2023 |
| Cowen & Co. | Outperform | Outperform | Maintain | Oct 17, 2022 |
| CFRA | Hold | Hold | Maintain | May 3, 2022 |
| Raymond James | Market Perform | Outperform | Downgrade | Nov 16, 2021 |
| Guggenheim | Buy | Buy | Maintain | Mar 21, 2021 |
| Bank of America | Underperform | Neutral | Downgrade | Feb 11, 2020 |
| KeyBanc | Overweight | Downgrade | Jul 10, 2019 | |
| BMO Capital | Market Perform | Market Perform | Maintain | Oct 26, 2018 |
| Berenberg | Buy | Buy | Maintain | Sep 20, 2018 |
| Argus | Buy | Buy | Maintain | May 5, 2018 |
| Moffett Nathanson | Buy | Buy | Maintain | Apr 9, 2018 |
| Mitsubishi UFJ | Overweight | Overweight | Maintain | Jan 10, 2018 |
| Goldman Sachs | Buy | Neutral | Upgrade | Dec 19, 2017 |
| William Blair | Outperform | Outperform | Maintain | Sep 22, 2017 |
| Macquarie | Neutral | Neutral | Maintain | Apr 7, 2017 |
| Needham | Buy | Buy | Maintain | Apr 4, 2017 |
| Leerink Swann | Outperform | Market Perform | Upgrade | Jan 16, 2017 |
| Avondale Partners | Outperform | Market Perform | Upgrade | Oct 4, 2016 |
| Stifel Nicolaus | Hold | Sell | Upgrade | Oct 3, 2016 |
| SunTrust Robinson Humphrey | Buy | Buy | Maintain | Jul 21, 2016 |
| Canaccord Genuity | Buy | Buy | Maintain | Jun 7, 2016 |
| Stephens & Co. | Equal Weight | Overweight | Downgrade | Apr 29, 2016 |
| BB&T Capital | Buy | Buy | Maintain | Nov 11, 2015 |
| FBR Capital | Perform | Outperform | Downgrade | Nov 21, 2014 |
| ISI Group | Hold | Buy | Downgrade | Oct 30, 2014 |
| Cantor Fitzgerald | Hold | Sell | Upgrade | May 29, 2014 |
| Evercore Partners | Overweight | Equal Weight | Upgrade | Dec 4, 2013 |
| Sterne Agee | Buy | Buy | Maintain | Sep 18, 2013 |
| McNicoll Lewis Vlak | Buy | Buy | Maintain | Jul 30, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $354. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Robert W. Baird | Analyst unavailable | $375 | $340.43 | +5.9% | Oct 22, 2026 |
| Argus Research | David Toung | $380 | $340 | +7.3% | Oct 20, 2026 |
| UBS | Analyst unavailable | $400 | $341.41 | +13.0% | Oct 16, 2026 |
| RBC Capital | Ryan Halsted | $330 | $316.13 | -6.8% | Aug 19, 2026 |
| Morgan Stanley | Analyst unavailable | $346 | $323.29 | -2.3% | Aug 7, 2026 |
| Robert W. Baird | Analyst unavailable | $370 | $313.37 | +4.5% | Aug 6, 2026 |
| UBS | Kevin Caliendo | $430 | $313.51 | +21.5% | Aug 6, 2026 |
| Evercore ISI | Analyst unavailable | $350 | $317.22 | -1.1% | Aug 6, 2026 |
| Barclays | Analyst unavailable | $350 | $279.57 | -1.1% | Jun 10, 2026 |
| Wells Fargo | Stephen Baxter | $331 | $261.08 | -6.5% | May 11, 2026 |
| Morgan Stanley | Analyst unavailable | $342 | $265.58 | -3.4% | May 8, 2026 |
| UBS | Analyst unavailable | $412 | $256.01 | +16.4% | May 7, 2026 |
| Evercore ISI | Analyst unavailable | $360 | $324.93 | +1.7% | Apr 8, 2026 |
| Morgan Stanley | Analyst unavailable | $380 | $334.15 | +7.3% | Mar 17, 2026 |
| Barclays | Analyst unavailable | $425 | $351.06 | +20.1% | Feb 13, 2026 |
| Wells Fargo | Analyst unavailable | $429 | $363.27 | +21.2% | Feb 10, 2026 |
| Evercore ISI | Analyst unavailable | $420 | $354.83 | +18.6% | Feb 5, 2026 |
| Morgan Stanley | Analyst unavailable | $400 | $350.54 | +13.0% | Jan 29, 2026 |
| Jefferies | Brian Tanquilut | $440 | $351.75 | +24.3% | Jan 22, 2026 |
| Robert W. Baird | Eric Coldwell | $415 | $345.3 | +17.2% | Jan 13, 2026 |
| Robert W. Baird | Analyst unavailable | $392 | $345.64 | +10.7% | Dec 16, 2025 |
| Barclays | Analyst unavailable | $400 | $337.82 | +13.0% | Dec 8, 2025 |
| UBS | Kevin Caliendo | $415 | $363.58 | +17.2% | Nov 7, 2025 |
| Evercore ISI | Analyst unavailable | $400 | $352.13 | +13.0% | Nov 6, 2025 |
| Mizuho Securities | Steven Valiquette | $340 | $333.17 | -4.0% | Oct 30, 2025 |
| UBS | Analyst unavailable | $380 | $334 | +7.3% | Oct 27, 2025 |
| Mizuho Securities | Steven Valiquette | $334 | $319.61 | -5.6% | Oct 16, 2025 |
| Evercore ISI | Analyst unavailable | $340 | $308.71 | -4.0% | Oct 8, 2025 |
| Wells Fargo | Stephen Baxter | $354 | $289.15 | +0.0% | Aug 13, 2025 |
| Morgan Stanley | Erin Wright | $330 | $295.68 | -6.8% | Jul 16, 2025 |
| Morgan Stanley | Erin Wright | $288 | $284.54 | -18.6% | Apr 15, 2025 |
| Citigroup | Daniel Grosslight | $284 | $229.34 | -19.8% | Sep 18, 2024 |
| Bank of America Securities | Allen Lutz | $245 | $234.53 | -30.8% | Sep 18, 2024 |
| Robert W. Baird | David Rodgers | $283 | $236.24 | -20.1% | Sep 6, 2024 |
| Robert W. Baird | David Rodgers | $287 | $237.88 | -18.9% | Aug 1, 2024 |
| Robert W. Baird | David Rodgers | $280 | $216.21 | -20.9% | May 29, 2024 |
| Robert W. Baird | David Rodgers | $275 | $242.04 | -22.3% | Apr 5, 2024 |
| Argus Research | David Toung | $270 | $245.8 | -23.7% | Apr 4, 2024 |
| Mizuho Securities | Ann Hynes | $174 | $166.87 | -50.8% | May 3, 2023 |
| Argus Research | Analyst unavailable | $190 | $164.83 | -46.3% | Jan 12, 2023 |
| Morgan Stanley | Analyst unavailable | $176 | $151.31 | -50.3% | Aug 22, 2022 |
| Credit Suisse | Analyst unavailable | $175 | $143.05 | -50.6% | Aug 4, 2022 |
| Argus Research | Analyst unavailable | $170 | $141.55 | -52.0% | Jul 20, 2022 |
| Evercore ISI | Elizabeth Anderson | $150 | $140.4 | -57.6% | Jul 19, 2022 |
| UBS | Kevin Caliendo | $174 | $145.02 | -50.8% | Jun 23, 2022 |
| Deutsche Bank | George Hill | $178 | $145.76 | -49.7% | Jun 10, 2022 |
| Cowen & Co. | Analyst unavailable | $170 | $145.62 | -52.0% | Jun 9, 2022 |
| Evercore ISI | Elizabeth Anderson | $165 | $150.01 | -53.4% | Jun 2, 2022 |
| Morgan Stanley | Analyst unavailable | $175 | $156.08 | -50.6% | May 27, 2022 |
| Deutsche Bank | Analyst unavailable | $168 | $155.19 | -52.5% | May 5, 2022 |
| Mizuho Securities | Analyst unavailable | $162 | $154.86 | -54.2% | May 5, 2022 |
| Barclays | Steven Valiquette | $152 | $136.01 | -57.1% | Jan 11, 2022 |
| Morgan Stanley | Ricky Goldwasser | $142 | $124.77 | -59.9% | Dec 17, 2021 |
| Deutsche Bank | George Hill | $153 | $124.93 | -56.8% | Nov 12, 2021 |
| UBS | Kevin Caliendo | $144 | $117.98 | -59.3% | Aug 11, 2021 |
Track every rating change on COR the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationCencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting.…
Historical context
All COR earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| CVS CVS Health Corp. | FY2026 Q3 · Calendar Q4 2026 | — | -12.5% | CVS raises 2026 outlook and plans a two-company separation |
| PODD Insulet Corp. | FY2026 Q3 · Calendar Q4 2026 | — | +6.6% | Insulet raises 2026 growth outlook as customer base and international sales expand |
| RPRX Royalty Pharma plc | FY2026 Q3 · Calendar Q4 2026 | — | +1.4% | Royalty Pharma Raises Guidance as Receipts and Co-Funding Expand |
| ZBH Zimmer Biomet Holdings, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +14.6% | Zimmer Biomet raises 2026 outlook as hip and technology growth offset knee weakness |
| MDLN Medline Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +16.2% | Medline Raises 2026 Organic Sales Outlook on 10% Q3 Growth |
| NVO Novo Nordisk A/S | FY2026 Q3 · Calendar Q4 2026 | — | +6.4% | Novo Nordisk Q3: obesity demand supports growth, pricing and LOE remain risks |
Latest beats and misses
Who reports nextBeat on EPS
- UNMAFY2026 Q3 · November 3, 2026+1.9% EPS+0.5% move
- UNMFY2026 Q3 · November 3, 2026+1.9% EPS-17.8% move
- IFFFY2026 Q3 · November 3, 2026+2.1% EPS-4.9% move
- JKHYFY2027 Q1 · November 3, 2026+10.1% EPS+10.8% move
- HL-PBFY2026 Q3 · November 3, 2026+54.0% EPS— move
- SUFY2026 Q3 · November 3, 2026+20.9% EPS-4.5% move
Missed on EPS
- OCFY2026 Q3 · November 4, 2026-20.5% EPS+8.5% move
- OHIFY2026 Q3 · November 3, 2026-42.5% EPS+3.5% move
- MOSFY2026 Q3 · November 3, 2026-1656.0% EPS+17.4% move
- OVVFY2026 Q3 · November 3, 2026-2.0% EPS-5.1% move
- BSACFY2026 Q3 · October 30, 2026-20.0% EPS-3.0% move
- TXFY2026 Q3 · November 3, 2026-24.9% EPS-0.0% move
Get the COR recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-11-04T17:12:16.983312+00:00
- FN2 earnings calendar · 2026-11-04T01:23:13.345574+00:00
- Polygon adjusted daily market bars · 2026-11-04T23:30:47.966081+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-04T23:30:47.962926+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-04. For educational purposes only; not investment advice.